Crispr Therapeutics AG Form 4 insider transactions

CEO Samarth Kulkarni reports the acquisition of stock options and restricted stock units in CRISPR Therapeutics.

Chief Financial Officer of CRISPR Therapeutics, Raju Prasad, reports acquisition and disposal of common shares and derivative securities.

Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics AG, reports the acquisition of stock options and restricted stock units.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, received stock options and restricted stock units on March 14, 2025.

CEO Samarth Kulkarni reports acquisition and disposal of CRISPR Therapeutics shares related to vesting of restricted stock units and tax obligations.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the acquisition and disposal of common shares and restricted stock units related to vesting and tax obligations.

Julianne Bruno, COO of CRISPR Therapeutics, reports the acquisition and disposal of common shares and restricted stock units related to vesting and tax obligations.

Director John Greene of CRISPR Therapeutics AG reports purchasing and disposing of common shares on February 26, 2025.

CEO Samarth Kulkarni sold 18,360 common shares of CRISPR Therapeutics at an average price of $55.205 under a pre-arranged 10b5-1 trading plan.

CEO Samarth Kulkarni reports stock sales to cover tax obligations and vesting of restricted stock units.

Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting and sale of common shares to cover tax obligations.

CRISPR Therapeutics CEO, Samarth Kulkarni, exercised stock options and acquired 13,751 common shares at a price of $16.21 per share on December 24, 2024.

CRISPR Therapeutics CEO Samarth Kulkarni sold 15,000 common shares at a weighted average price of $55.1043, as part of a pre-arranged 10b5-1 trading plan.

CRISPR Therapeutics CEO Samarth Kulkarni sold a total of 30,000 common shares in multiple transactions under a pre-arranged 10b5-1 trading plan.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics, received stock options for 18,333 shares and restricted stock units for 30,000 shares on October 16, 2024.

Julianne Bruno, Chief Operating Officer of CRISPR Therapeutics AG, was granted stock options for 18,333 common shares on October 16, 2024.

CEO of CRISPR Therapeutics, Samarth Kulkarni, receives stock options for 55,000 shares and 400,000 restricted stock units.

Chief Medical Officer of CRISPR Therapeutics, Naimish Patel, reports the acquisition of stock options.

Raju Prasad, CFO of CRISPR Therapeutics, was granted stock options for 18,333 common shares and 15,000 restricted stock units on October 16, 2024.

James R. Kasinger, General Counsel and Secretary of CRISPR Therapeutics AG, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

CEO Samarth Kulkarni reports acquisition and disposal of CRISPR Therapeutics shares related to vesting of restricted stock units and tax obligations.

CEO Samarth Kulkarni reports a gift of 100,000 common shares and a transfer of shares from a GRAT.

Julianne Bruno, COO of CRISPR Therapeutics, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Director Simeon George of CRISPR Therapeutics AG reports the acquisition of stock options on May 30, 2024.

Director Ali Behbahani acquired 13,000 stock options in CRISPR Therapeutics AG on May 30, 2024, according to a recent SEC filing.

Director Maria Fardis reports the acquisition of stock options for 13,000 common shares of CRISPR Therapeutics AG.

Director Sandesh Mahatme acquired stock options for 13,000 common shares in CRISPR Therapeutics.

Director Rommel Christian of CRISPR Therapeutics AG reports acquisition of stock options.

Director John Greene acquired stock options for 13,000 common shares in CRISPR Therapeutics, vesting monthly over the next year.